HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib-Reference-Cited by-同舟云学术

HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib

Published:2014-03 Issue:3 Volume:9 Page:285-294
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Fang Douglas D.,Zhang Bin,Gu Qingyang,Lira Maruja,Xu Qiang,Sun Hongye,Qian Maoxiang,Sheng Weiqi,Ozeck Mark,Wang Zhenxiong,Zhang Cathy,Chen Xinsheng,Chen Kevin X.,Li Jian,Chen Shu-Hui,Christensen James,Mao Mao,Chan Chi-Chung

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference41 articles.

1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

2. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

3. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

4. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma;Christensen;Mol Cancer Ther,2007

5. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer;Kwak;N Engl J Med,2010

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers;Nature Communications;2024-06-14

2. Genomic Landscape of NSCLC in the Republic of Ireland;JTO Clinical and Research Reports;2024-02

3. Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers;2024-01-17

4. ACTB may serve as a predictive marker for the efficacy of lenvatinib in patients with HBV-related early-stage hepatocellular carcinoma following partial hepatectomy: a retrospective cohort study;Journal of Gastrointestinal Oncology;2023-12

5. Targeted therapy for rare lung cancers: Status, challenges, and prospects;Molecular Therapy;2023-07